India to Israel: Amoxicillin Export Trade Route

To import Amoxicillin formulations into Israel, the following steps must be undertaken:

1. Appointment of a Local Representative: The applicant must be an Israeli resident or a corporation registered in Israel. The application should be signed by a licensed pharmacist approved by the MOH.

2. Submission of Registration Application: The application is submitted to the MOH's Registration Department, adhering to the Pharmacists Regulations (Preparations) of 1986. The dossier should be compiled in the Common Technical Document (CTD) format, encompassing quality, safety, and efficacy data.

3. Quality Certificate: Concurrently, a Quality Certificate application must be submitted to the Institute of Medicine Review and Standards Institute (IMRSI).

4. Approval Timeline: The MOH aims to notify applicants of registration decisions within 270 days of filing. However, for drugs already approved by the U.S. FDA or EMA, this period may be shortened to approximately 180 days, provided a full approval package is submitted.

5. Registration Fees: The fee for registering a new drug is 6,071 shekels.

6. GMP Certification: The manufacturing facility must possess Good Manufacturing Practice (GMP) certification from a recognized authority. The MOH may require GMP inspections of foreign manufacturing sites to ensure compliance with Israeli standards.

Indian manufacturers exporting Amoxicillin formulations to Israel must comply with the following GMP standards:

1. GMP Certification: Facilities must hold GMP certification from a competent authority recognized by the MOH, such as the U.S. FDA, EMA, or WHO.

2. Compliance with Revised Schedule M: As of January 6, 2024, India's Ministry of Health revised Schedule M of the Drugs and Cosmetics Rules to align with global GMP standards. The revision introduced a pharmaceutical quality system (PQS), quality risk management (QRM), and product quality review (PQR). Manufacturers must ensure compliance with these updated standards.

3. Inspection and Compliance: The MOH may conduct inspections of Indian manufacturing facilities to verify GMP compliance. Recent inspections have revealed significant violations, including inadequate hygiene and data integrity issues. For instance, in December 2024, an Indian manufacturer faced severe GMP violations, leading to regulatory actions.

Several regulatory changes between 2024 and 2026 have impacted Indian pharmaceutical exports to Israel:

1. Revised Schedule M Implementation: On January 6, 2024, India's Ministry of Health updated Schedule M to enhance GMP standards. This revision aims to align India's pharmaceutical manufacturing practices with global standards, affecting all exporters, including those supplying to Israel.

2. Extension for GMP Compliance: Recognizing the challenges faced by small and medium-sized enterprises (SMEs), the Indian government extended the deadline for compliance with the revised Schedule M to December 31, 2025. This extension provides additional time for SMEs to upgrade their facilities and processes to meet the enhanced GMP standards.

3. Regulatory Actions on Non-Compliance: Between 2024 and 2025, Indian regulatory authorities intensified actions against pharmaceutical companies failing to meet GMP standards. This period saw the cancellation of licenses for 64 companies and the shutdown of 17 drug testing laboratories due to non-compliance. Such actions underscore the importance of adhering to GMP standards for maintaining export eligibility.

These developments highlight the critical need for Indian exporters to Israel to ensure strict compliance with both Indian and Israeli regulatory requirements to maintain market access and uphold product quality standards.

In 2025, Israel's antibiotic imports experienced a significant decline, both in volume and value. Despite this downturn, the demand for Amoxicillin formulations remains influenced by factors such as the prevalence of bacterial infections, healthcare expenditure, and the country's aging population. Israel's universal health coverage ensures widespread access to essential medications, including antibiotics. While specific data on domestic production versus imports of Amoxicillin formulations is limited, the presence of major pharmaceutical companies like Teva Pharmaceutical Industries Ltd. suggests a combination of local manufacturing and imports to meet national demand.

Israel imposes a 0% import duty on pharmaceutical products classified under HS code 30041030, which includes Amoxicillin formulations. Additionally, a Value Added Tax (VAT) of 17% is applied to the total value of imported goods, calculated on the Cost, Insurance, and Freight (CIF) basis. There are no specific Free Trade Agreements (FTAs) between India and Israel that further affect pharmaceutical tariffs, nor are there any anti-dumping duties currently imposed on these products.

India is a significant supplier of Amoxicillin formulations to Israel, accounting for approximately 2.5% of India's total Amoxicillin formulation exports, valued at $15.0 million USD across 81 shipments. The primary exporters include MEDOPHARM and AUROBINDO PHARMA LTD. Major Israeli buyers are M/S. UNRWA - HEAD FIELD LOGISTICS O and TEVA ISRAEL LTD. Other notable suppliers to Israel's antibiotic market include China and Hungary, with China being a leading source. While specific pricing data is not readily available, India's competitive pricing and established pharmaceutical industry position it favorably against competitors from China and the European Union.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 31.9% of the United States' finished dosage form (FDF) antibiotic imports between 2020 and 2024. This prominence is underpinned by a robust manufacturing infrastructure, with 752 FDA-approved sites, 2,050 WHO-GMP certified plants, and 286 EDQM-approved facilities as of 2024.

The country's extensive production capacity for finished dosage forms, including tablets, capsules, and syrups containing Amoxicillin, enables economies of scale that translate into cost advantages. Additionally, India's pharmaceutical sector benefits from a skilled workforce and a favorable regulatory environment, further enhancing its competitiveness in the global market.

When comparing Amoxicillin formulations from India, China, and the European Union (EU), several factors come into play:

• Price per Unit: In the third quarter of 2025, Amoxicillin Trihydrate prices in India were approximately $23,500 per metric ton, while in China, prices stood at $21,370 per metric ton. EU prices are generally higher due to stringent regulatory standards and higher production costs.

• Quality Perception: India's pharmaceutical industry is recognized for its adherence to international quality standards, with numerous WHO-GMP and FDA-approved facilities. China has made significant strides in quality assurance but has faced challenges related to regulatory compliance. The EU maintains a strong reputation for high-quality pharmaceutical products, albeit at higher costs.

• Regulatory Acceptance in Israel: Israel's regulatory framework is aligned with international standards, facilitating the acceptance of pharmaceuticals from countries with stringent regulatory oversight. India's compliance with WHO-GMP and FDA standards positions it favorably in the Israeli market.

• Supply Reliability Track Record: India has a well-established track record of supplying Amoxicillin formulations to various global markets, including Israel. The country's extensive manufacturing capacity and experience in international trade contribute to a reliable supply chain.

India's pharmaceutical industry boasts significant manufacturing capacity for finished dosage forms, including Amoxicillin formulations. The country's facilities are equipped with advanced packaging and cold chain capabilities to ensure product integrity during transportation.

While there have been instances of regulatory scrutiny, leading manufacturers have demonstrated a commitment to compliance and quality improvement. For example, Granules India Limited received U.S. FDA approval for its Hyderabad facility in November 2025, marking a significant milestone in expanding its finished dosage manufacturing capabilities.

There are no significant capacity constraints reported among top Indian formulation manufacturers. On the contrary, companies are actively expanding their facilities and obtaining necessary regulatory approvals to meet global demand.

For Israeli buyers sourcing Amoxicillin formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Establish clear payment terms, commonly including letters of credit or advance payments, to build trust and ensure timely transactions.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and compliance checks, to ensure suppliers meet regulatory standards and quality expectations.

• Regulatory Compliance: Verify that the selected suppliers have the necessary WHO-GMP and FDA approvals to facilitate smooth importation and regulatory acceptance in Israel.

By implementing these strategies, Israeli buyers can effectively source high-quality Amoxicillin formulations from India, ensuring both cost-effectiveness and supply reliability.

1. Verify Ministry of Health (MOH) Israel Registration: Confirm that the Amoxicillin formulations are registered with the Israeli MOH, ensuring compliance with local regulatory requirements.

2. Assess GMP Certificate Validity: Obtain and review the supplier's Good Manufacturing Practice (GMP) certificate to ensure it is current and issued by a recognized authority.

3. Review Drug Master File (DMF): Examine the DMF for comprehensive information on the manufacturing process, controls, and specifications of the Amoxicillin formulations.

4. Evaluate Quality Management System (QMS): Ensure the supplier has a robust QMS in place, including standard operating procedures (SOPs), quality control measures, and documentation practices.

5. Confirm Minimum Acceptable Certifications: Verify that the supplier holds certifications such as WHO-GMP, ISO 9001, or other relevant international standards.

6. Conduct Supplier Reputation Assessment: Research the supplier's history, including any past regulatory actions, recalls, or quality issues.

7. Request Stability Data: Obtain stability data to ensure the product maintains its quality over its shelf life under various environmental conditions.

8. Perform Financial Due Diligence: Assess the financial stability of the supplier to ensure they can fulfill long-term supply commitments.

9. Plan for On-Site Audit: Schedule an on-site audit of the manufacturing facility to verify compliance with GMP and other quality standards.

10. Establish Quality Agreement: Draft and sign a quality agreement outlining the responsibilities and expectations of both parties regarding product quality and compliance.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for a specific batch, confirming that the product meets predefined specifications.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, which is essential for customs and regulatory purposes.

3. GMP Certificate: Demonstrates that the manufacturing facility complies with Good Manufacturing Practice standards, ensuring product quality and safety.

4. Stability Data: Includes studies conducted under various environmental conditions to confirm the product's shelf life and storage requirements.

5. Batch Records: Detailed documentation of the production process for each batch, ensuring traceability and consistency in manufacturing.

6. Drug Master File (DMF): Contains comprehensive information on the manufacturing process, controls, and specifications of the product, facilitating regulatory review.

7. Free Sale Certificate from CDSCO: Issued by the Central Drugs Standard Control Organization, indicating that the product is approved for sale in India and meets regulatory standards.

8. Insurance Certificates: Proof of liability insurance coverage, providing assurance of financial protection in case of product-related issues.

1. Recent Regulatory Actions: Suppliers with recent FDA warning letters or WHO-GMP suspensions may indicate compliance issues. For example, in March 2025, an Indian manufacturer received an FDA warning letter for significant GMP violations.

2. Unusually Low Pricing: Prices significantly below market rates may suggest compromised quality or substandard manufacturing practices.

3. Lack of Stability Data: Inability to provide comprehensive stability data raises concerns about the product's shelf life and efficacy.

4. No Export Track Record to Middle East: Suppliers without a history of exporting to Middle Eastern markets may lack experience with regional regulatory requirements.

5. Resistance to Factory Audits: Suppliers unwilling to allow on-site inspections may be attempting to conceal compliance or quality issues.

6. Frequent Product Recalls: A history of product recalls indicates potential quality control problems.

7. Inconsistent Documentation: Discrepancies or incomplete information in provided documents can signal reliability issues.

1. Pre-Audit Desktop Review: Conduct a thorough review of the supplier's documentation, including GMP certificates, SOPs, and previous audit reports, to identify potential areas of concern.

3. Post-Audit Corrective Action Expectations: Require the supplier to address any identified deficiencies within a specified timeframe, providing evidence of corrective actions taken.

4. Annual Re-Qualification Process: Implement a yearly review of the supplier's compliance and performance, including updated audits and documentation assessments.

5. Remote Monitoring Options: Utilize technology such as virtual audits, regular video conferences, and electronic document reviews to maintain oversight between on-site visits.

6. Cost Estimates and Timeline: Plan for audit visits to India, considering travel expenses, auditor fees, and time required for each phase. A typical on-site audit may take 3-5 days, with additional time for preparation and follow-up.